Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzomenib (DSP-5336) phase 1/2 study in acute leukemia and selected hematologic malignancies
jRCT2031210594Phase 2Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of enzomenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute leukemia of ambiguous lineage (ALAL) (5 arms), sponsored by Sumitomo Pharma. Started Mar 2022; status: recruiting.
02
Drugs
enzomenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on jRCT2031210594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210594.